-
1
-
-
0026500785
-
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: Phase III trial of Southeastern Cancer Study Group
-
Roth BJ, Johnson DH, Einhorn LH, et al: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: Phase III trial of Southeastern Cancer Study Group. J Clin Oncol 10:282-291, 1992
-
(1992)
J Clin Oncol
, vol.10
, pp. 282-291
-
-
Roth, B.J.1
Johnson, D.H.2
Einhorn, L.H.3
-
2
-
-
0025898914
-
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
-
Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855-861, 1991
-
(1991)
J Natl Cancer Inst
, vol.83
, pp. 855-861
-
-
Fukuoka, M.1
Furuse, K.2
Saijo, N.3
-
3
-
-
0025204765
-
A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer
-
Sculier JP, Klastersky J, Libert P, et al: A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer. Lung Cancer 6:110-118, 1990
-
(1990)
Lung Cancer
, vol.6
, pp. 110-118
-
-
Sculier, J.P.1
Klastersky, J.2
Libert, P.3
-
4
-
-
0023201152
-
Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small-cell lung cancer
-
Shepherd FA, Evans WK, MacCormick R, et al: Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small-cell lung cancer. Cancer Treat Rep 71:941-944, 1987
-
(1987)
Cancer Treat Rep
, vol.71
, pp. 941-944
-
-
Shepherd, F.A.1
Evans, W.K.2
MacCormick, R.3
-
6
-
-
0012115877
-
Neoplasms of the lung
-
Isselbacher KJ, Braunwald E, Wilson JD, et al (eds): New York, McGraw-Hill
-
Minna JD: Neoplasms of the lung, in Isselbacher KJ, Braunwald E, Wilson JD, et al (eds): Harrison's Principles of Internal Medicine. New York, McGraw-Hill, 1994, pp 1221-1229
-
(1994)
Harrison's Principles of Internal Medicine
, pp. 1221-1229
-
-
Minna, J.D.1
-
10
-
-
0003154770
-
Small-cell lung cancer
-
DeVita VT, Hellman S, Rosenberg SA (eds): Philadelphia, PA, Lippincott-Raven
-
Ihde DC, Pass HI, Glatstein EJ: Small-cell lung cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott-Raven, 1993, p 749
-
(1993)
Cancer, Principles and Practice of Oncology (Ed 4)
, pp. 749
-
-
Ihde, D.C.1
Pass, H.I.2
Glatstein, E.J.3
-
11
-
-
0030913459
-
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
-
Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997
-
(1997)
J Clin Oncol
, vol.15
, pp. 2090-2096
-
-
Ardizzoni, A.1
Hansen, H.2
Dombernowsky, P.3
-
12
-
-
0002429272
-
Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC): A multicenter phase II study
-
abstr 126
-
Depierre A, von Pawel J, Hans K, et al: Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC): A multicenter Phase II study. Lung Cancer 18:35, 1997 (abstr 126)
-
(1997)
Lung Cancer
, vol.18
, pp. 35
-
-
Depierre, A.1
Von Pawel, J.2
Hans, K.3
-
13
-
-
0000580721
-
Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A phase II study
-
abstr 513
-
Eckardt J, Gralla R, Palmer MC, et al: Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A Phase II study. Ann Oncol 7:107, 1996 (abstr 513)
-
(1996)
Ann Oncol
, vol.7
, pp. 107
-
-
Eckardt, J.1
Gralla, R.2
Palmer, M.C.3
-
14
-
-
0000313636
-
Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC)
-
abstr 1624
-
Eckardt J, Depierre A, Ardizzoni A, et al: Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer (SCLC). Proc Am Soc Clin Oncol, 16:452a, 1997 (abstr 1624)
-
(1997)
Proc Am Soc Clin Oncol
, vol.16
-
-
Eckardt, J.1
Depierre, A.2
Ardizzoni, A.3
-
17
-
-
0026608875
-
Management of small-cell lung cancer
-
Hansen HH: Management of small-cell lung cancer. Lancet 339:846-849, 1992
-
(1992)
Lancet
, vol.339
, pp. 846-849
-
-
Hansen, H.H.1
-
18
-
-
0027162262
-
Predictors of survival following relapse or progression of small cell lung cancer
-
Albain KS, Crowley JJ, Hutchins L, et al: Predictors of survival following relapse or progression of small cell lung cancer. Cancer 72:1184-1191, 1993
-
(1993)
Cancer
, vol.72
, pp. 1184-1191
-
-
Albain, K.S.1
Crowley, J.J.2
Hutchins, L.3
-
19
-
-
0029758947
-
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase poison topotecan
-
Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase poison topotecan. J Clin Oncol 14:2785-2790, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2785-2790
-
-
Perez-Soler, R.1
Glisson, B.S.2
Lee, J.S.3
-
20
-
-
0025130651
-
Prolonged administration of oral etoposide in patients with relapsed small-cell lung cancer: A phase II trial
-
Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
-
(1990)
J Clin Oncol
, vol.8
, pp. 1613-1617
-
-
Johnson, D.H.1
Greco, F.A.2
Strupp, J.3
-
21
-
-
0030608237
-
Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomized trial. Medical Research Council Lung Cancer Working Party
-
Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomized trial. Medical Research Council Lung Cancer Working Party. Lancet 348:563-566, 1996
-
(1996)
Lancet
, vol.348
, pp. 563-566
-
-
-
22
-
-
0030946011
-
Five day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
-
Souhami RL, Spiro SG, Rudd RM, et al: Five day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89:577-580, 1997
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 577-580
-
-
Souhami, R.L.1
Spiro, S.G.2
Rudd, R.M.3
-
23
-
-
0029071979
-
Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study
-
Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
-
(1995)
J Clin Oncol
, vol.13
, pp. 1430-1435
-
-
Ettinger, D.S.1
Finkelstein, D.M.2
Sarma, R.P.3
-
24
-
-
0001098464
-
A phase II trial of Taxol and G-CSF in previously untreated SCLC
-
abstr 1076
-
Kirschling RJ, Jung JH, Jett JR: A phase II trial of Taxol and G-CSF in previously untreated SCLC. Proc Am Soc Clin Oncol 13:326, 1994 (abstr 1076)
-
(1994)
Proc Am Soc Clin Oncol
, vol.13
, pp. 326
-
-
Kirschling, R.J.1
Jung, J.H.2
Jett, J.R.3
-
25
-
-
0029608619
-
Phase II trial of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer
-
Latreille J, Cormier Y, Martins H, et al: Phase II trial of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13:343-345, 1996
-
(1996)
Invest New Drugs
, vol.13
, pp. 343-345
-
-
Latreille, J.1
Cormier, Y.2
Martins, H.3
-
26
-
-
0344367790
-
Taxotere is active in small cell lung cancer (SCLC). A phase II trial of the EORTC Early Clinical Trials Group (ECTG)
-
abstr 849
-
Smyth JF, Bowman A, Smith I, et al: Taxotere is active in small cell lung cancer (SCLC). A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Eur J Cancer 29A:154, 1993 (suppl 6, abstr 849)
-
(1993)
Eur J Cancer
, vol.29 A
, Issue.6 SUPPL.
, pp. 154
-
-
Smyth, J.F.1
Bowman, A.2
Smith, I.3
-
27
-
-
0028071210
-
Activity of docetaxel (Taxotere) in small cell lung cancer
-
Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 30A:1058-1060, 1994
-
(1994)
Eur J Cancer
, vol.30 A
, pp. 1058-1060
-
-
Smyth, J.F.1
Smith, I.E.2
Sessa, C.3
-
28
-
-
0028297564
-
Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group
-
Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small-cell lung cancer (SCLC): A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5:283-285, 1994
-
(1994)
Ann Oncol
, vol.5
, pp. 283-285
-
-
Cormier, Y.1
Eisenhauer, E.2
Muldal, A.3
-
29
-
-
13344270908
-
Phase II study of vinorelbine in heavily previously treated small cell lung cancer
-
Furuse K, Kubota K, Kawahara M, et al: Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 53:169-172, 1996
-
(1996)
Oncology
, vol.53
, pp. 169-172
-
-
Furuse, K.1
Kubota, K.2
Kawahara, M.3
-
30
-
-
0027248286
-
Phase II study of Vinorelbine (Navelbine) in previously treated small cell lung cancer patients
-
Jassem J, Karnicka-Mlodkowska H, Van Pottelsberghe C, et al: Phase II study of Vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A:1720-1722, 1993
-
(1993)
Eur J Cancer
, vol.29 A
, pp. 1720-1722
-
-
Jassem, J.1
Karnicka-Mlodkowska, H.2
Van Pottelsberghe, C.3
-
31
-
-
0029074323
-
Pilot study of irinotecan in refractory small cell lung cancer
-
Fujita A, Takabatake H, Tagaki S, et al: Pilot study of irinotecan in refractory small cell lung cancer. Gan To Kagaku Ryoho 22:889-893, 1995
-
(1995)
Gan To Kagaku Ryoho
, vol.22
, pp. 889-893
-
-
Fujita, A.1
Takabatake, H.2
Tagaki, S.3
-
32
-
-
0026680292
-
CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
-
Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
-
(1992)
J Clin Oncol
, vol.10
, pp. 1225-1229
-
-
Masuda, N.1
Fukuoka, M.2
Kusunoki, Y.3
-
33
-
-
0344799567
-
CPT-11 (irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results)
-
Pujol JL, Le Chevalier T, Douillard JY, et al: CPT-11 (irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results). Eur J Cancer 31:821, 1995 (suppl 5)
-
(1995)
Eur J Cancer
, vol.31
, Issue.5 SUPPL.
, pp. 821
-
-
Pujol, J.L.1
Le Chevalier, T.2
Douillard, J.Y.3
-
34
-
-
0029790139
-
Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: An Eastern cooperative oncology group trial
-
Schiller JH, Kim KM, Hutson P, et al: Phase II study of topotecan in patients with extensive stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996
-
(1996)
J Clin Oncol
, vol.14
, pp. 2345-2352
-
-
Schiller, J.H.1
Kim, K.M.2
Hutson, P.3
-
35
-
-
0029993118
-
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel
-
letter
-
Miller AA, Lilenbaum RC, Lynch TJ, et al: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 14:1964-1965, 1996 (letter)
-
(1996)
J Clin Oncol
, vol.14
, pp. 1964-1965
-
-
Miller, A.A.1
Lilenbaum, R.C.2
Lynch, T.J.3
-
36
-
-
0030665426
-
Clinical status and optimal use of topotecan
-
Takimoto CH, Arbuck SG: Clinical status and optimal use of topotecan. Oncology 11:1635-1646, 1997
-
(1997)
Oncology
, vol.11
, pp. 1635-1646
-
-
Takimoto, C.H.1
Arbuck, S.G.2
-
37
-
-
0002963913
-
Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy
-
abstr 38
-
Jett JR, Day R, Levitt M, et al: Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 18:13, 1997 (suppl 1, abstr 38)
-
(1997)
Lung Cancer
, vol.18
, Issue.1 SUPPL.
, pp. 13
-
-
Jett, J.R.1
Day, R.2
Levitt, M.3
-
38
-
-
0002091930
-
Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 depletion: A NYGOG study
-
abstr 326
-
Hochster H, Speyer J, Wadler S, et al: Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 depletion: A NYGOG study. Ann Oncol 7:69, 1996 (abstr 326)
-
(1996)
Ann Oncol
, vol.7
, pp. 69
-
-
Hochster, H.1
Speyer, J.2
Wadler, S.3
|